Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production.

Khanim FL, Merrick BA, Giles HV, Jankute M, Jackson JB, Giles LJ, Birtwistle J, Bunce CM, Drayson MT.

Blood Cancer J. 2011 Oct;1(10):e39. doi: 10.1038/bcj.2011.38. Epub 2011 Oct 21.

2.

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.

Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, Harding S, Bradwell AR, Mead G.

BMC Nephrol. 2008 Sep 22;9:11. doi: 10.1186/1471-2369-9-11.

3.

A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion.

Circu ML, Dykes SS, Carroll J, Kelly K, Galiano F, Greer A, Cardelli J, El-Osta H.

PLoS One. 2016 Jan 19;11(1):e0146931. doi: 10.1371/journal.pone.0146931. eCollection 2016. Erratum in: PLoS One. 2016;11(3):e0151718.

4.

In vitro trypanocidal activity of the anti-helminthic drug niclosamide.

Merschjohann K, Steverding D.

Exp Parasitol. 2008 Apr;118(4):637-40. doi: 10.1016/j.exppara.2007.12.001. Epub 2007 Dec 15.

PMID:
18226810
5.

The pathogenesis of acute kidney impairment in patients with multiple myeloma.

Batuman V.

Adv Chronic Kidney Dis. 2012 Sep;19(5):282-6. doi: 10.1053/j.ackd.2012.04.009. Review.

PMID:
22920637
6.

Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells.

Wang YC, Chao TK, Chang CC, Yo YT, Yu MH, Lai HC.

PLoS One. 2013 Sep 18;8(9):e74538. doi: 10.1371/journal.pone.0074538. eCollection 2013.

7.

The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.

Liao Z, Nan G, Yan Z, Zeng L, Deng Y, Ye J, Zhang Z, Qiao M, Li R, Denduluri S, Wang J, Wei Q, Geng N, Zhao L, Lu S, Wang X, Zhou G, Luu HH, Haydon RC, He TC, Wang Z.

Curr Cancer Drug Targets. 2015;15(8):726-38.

PMID:
26118906
8.

The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma.

Khong T, Sharkey J, Spencer A.

Haematologica. 2008 Jun;93(6):860-9. doi: 10.3324/haematol.12261. Epub 2008 Apr 28.

9.

Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, Kyle RA, Leung N.

J Am Soc Nephrol. 2011 Jun;22(6):1129-36. doi: 10.1681/ASN.2010080857. Epub 2011 Apr 21.

10.
11.

[Serum free light chains for diagnosis and follow-up of multiple myeloma].

Jung S, Kim M, Lim J, Kim Y, Han K, Min CK, Min WS.

Korean J Lab Med. 2008 Jun;28(3):169-73. doi: 10.3343/kjlm.2008.28.3.169. Korean.

12.

The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling.

Chen M, Wang J, Lu J, Bond MC, Ren XR, Lyerly HK, Barak LS, Chen W.

Biochemistry. 2009 Nov 3;48(43):10267-74. doi: 10.1021/bi9009677.

13.

Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.

Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, Sun X, Wu Y, Zhou J, Pan J.

Cancer Res. 2010 Mar 15;70(6):2516-27. doi: 10.1158/0008-5472.CAN-09-3950. Epub 2010 Mar 9.

14.

Growth inhibition of ovarian tumor-initiating cells by niclosamide.

Yo YT, Lin YW, Wang YC, Balch C, Huang RL, Chan MW, Sytwu HK, Chen CK, Chang CC, Nephew KP, Huang T, Yu MH, Lai HC.

Mol Cancer Ther. 2012 Aug;11(8):1703-12. doi: 10.1158/1535-7163.MCT-12-0002. Epub 2012 May 10.

15.

The evolving use of serum free light chain assays in haematology.

Pratt G.

Br J Haematol. 2008 May;141(4):413-22. doi: 10.1111/j.1365-2141.2008.07079.x. Epub 2008 Mar 3. Review.

PMID:
18318757
16.

Nanoliposomal Encapsulation Enhances In Vivo Anti-Tumor Activity of Niclosamide against Melanoma.

Hatamipour M, Jaafari MR, Momtazi-Borojeni AA, Ramezani M, Sahebkar A.

Anticancer Agents Med Chem. 2019 Jul 5. doi: 10.2174/1871520619666190705120011. [Epub ahead of print]

PMID:
31284876
17.

Addition of niclosamide to palladium(II) saccharinate complex of terpyridine results in enhanced cytotoxic activity inducing apoptosis on cancer stem cells of breast cancer.

Karakas D, Cevatemre B, Aztopal N, Ari F, Yilmaz VT, Ulukaya E.

Bioorg Med Chem. 2015 Sep 1;23(17):5580-6. doi: 10.1016/j.bmc.2015.07.026. Epub 2015 Jul 18.

PMID:
26234907
18.

Serum free light chains for monitoring multiple myeloma.

Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR.

Br J Haematol. 2004 Aug;126(3):348-54.

PMID:
15257706
19.

Anticancer effects of niclosamide in human glioblastoma.

Wieland A, Trageser D, Gogolok S, Reinartz R, Höfer H, Keller M, Leinhaas A, Schelle R, Normann S, Klaas L, Waha A, Koch P, Fimmers R, Pietsch T, Yachnis AT, Pincus DW, Steindler DA, Brüstle O, Simon M, Glas M, Scheffler B.

Clin Cancer Res. 2013 Aug 1;19(15):4124-36. doi: 10.1158/1078-0432.CCR-12-2895.

20.

Autophagy inhibition enhances isobavachalcone-induced cell death in multiple myeloma cells.

Zhao S, Ma CM, Liu CX, Wei W, Sun Y, Yan H, Wu YL.

Int J Mol Med. 2012 Oct;30(4):939-44. doi: 10.3892/ijmm.2012.1066. Epub 2012 Jul 16.

PMID:
22824846

Supplemental Content

Support Center